Fallopian Tube Cancer is a rare but serious gynecological cancer requiring precise diagnosis and expert care. India offers world-class treatment at a fraction of international costs, with comprehensive oncology support. The average cost for treatment in India ranges from $4,000 to $7,000.
Fallopian Tube Cancer originates in the tubes connecting the ovaries to the uterus. It is rare, accounting for less than 2% of all gynecological cancers. It may be primary (starting in the tubes) or secondary (spread from nearby organs like the ovaries or uterus).
Most cases occur in women over 50 and are often linked to genetic mutations like BRCA1/2. Its similarity to ovarian cancer can sometimes delay diagnosis, making early detection crucial.
India follows international cancer care guidelines (like NCCN and ESMO) and uses a multi-modality approach.
|
Service |
Estimated Cost (USD) |
|
Initial Consultation |
$50 – $100 |
|
Imaging & Diagnostics |
$500 – $800 |
|
Surgery (Hysterectomy & BSO) |
$2,000 – $3,500 |
|
Chemotherapy (6 cycles) |
$1,500 – $2,400 |
|
Radiation Therapy (if required) |
$1,200 – $2,000 |
|
Targeted Therapy (if needed) |
$1,000 – $2,000/month |
|
Hospital Stay & Medications |
$700 – $1,200 |
|
Total Estimated Cost |
$4,000 – $7,000 |
|
Country |
Average Cost (USD) |
|
India |
$4,000 – $7,000 |
|
United States |
$25,000 – $40,000 |
|
Thailand |
$10,000 – $18,000 |
India delivers comparable quality at 70–85% lower cost.
Importance of Early Treatment
Starting treatment early ensures:
India’s advanced diagnostics and fast scheduling enable early-stage intervention.
Yes, especially if diagnosed early. Surgery combined with chemotherapy offers high survival rates.
Usually 3–5 months, including surgery and chemotherapy recovery.
Yes, including BRCA1/2 and other hereditary panels.
Many hospitals assist with insurance paperwork or accept direct billing if pre-approved.
No. English is widely spoken. Interpreters are available for Arabic, French, Spanish, and African languages.
You’ll receive treatment records, prescriptions, and teleconsultation access.
Most patients are fit to travel within 2–3 weeks after final treatment.